Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine.
A 56 year old woman with rheumatoid arthritis developed relapsing thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine. The presence of IgM or IgG antibodies or immune complexes reactive with autologous platelets could not be shown. Relapsing thrombocytopenia may indicate a genetically determined HLA-DR3 and B8 aberrant immunological response to stimuli such as certain second line drugs.
Wijnands
M J
MJ
University Hospital, Nijmegen, The Netherlands.
Allebes
W A
WA
Boerbooms
A M
AM
van de Putte
L B
LB
van Riel
P L
PL
D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006051:Aurothioglucose / Q000009:adverse effects*; D005260:Female; D015795:HLA-B8 Antigen / Q000032:analysis; D015803:HLA-DR3 Antigen / Q000032:analysis; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008875:Middle Aged; D012460:Sulfasalazine / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000235:genetics / Q000276:immunology
D015795:HLA-B8 Antigen; D015803:HLA-DR3 Antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D006051:Aurothioglucose; D012460:Sulfasalazine; D006886:Hydroxychloroquine